News & Views | Published:


How does lorcaserin facilitate weight loss and who will benefit?

Nature Reviews Endocrinologyvolume 14pages692693 (2018) | Download Citation

Pharmacotherapy for obesity, as an adjunct to targeted behavioural modifications, can facilitate weight loss. Previous serotonergic candidates have been withdrawn owing to undesirable cardiovascular effects. A new study in a large sample of high-risk patients shows lorcaserin treatment leads to no greater increase in cardiovascular problems than placebo — what does this result mean for personalized pharmacotherapy for obesity?

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    World Health Organisation. Obesity and overweight. WHO (2018).

  2. 2.

    Bastien, M. et al. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog. Cardiovasc. Dis 56, 369–381 (2014).

  3. 3.

    National Institute for Health and Clinical Excellence. Obesity: identification, assessment and management of overweight and obesity in children, young people and adults: partial update of CG43. NICE (2014).

  4. 4.

    Halford, J. C. G. et al. Pharmacological management of appetite suppression in obesity. Nat. Rev. Endocrinol. 6, 255–269 (2010).

  5. 5.

    Khera, R. et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA 315, 2424–2434 (2016).

  6. 6.

    Chan, E. W. et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes. Rev. 14, 383–392 (2013).

  7. 7.

    Bohula, E. A. et al. Cardiovascular safety of lorcaserin in overweight or obese patients. N. Engl. J. Med. 379, 1107–1117 (2018).

  8. 8.

    Roberts, C. A. et al. Tailoring pharmacotherapy to specific eating behaviours in obesity: can recommendations for personalised therapy be made from the current data? Acta Diabetol. 54, 715–725 (2017).

Download references

Author information


  1. Department of Psychological Sciences at the University of Liverpool, Liverpool, UK

    • Carl A. Roberts
    •  & Jason C. G. Halford


  1. Search for Carl A. Roberts in:

  2. Search for Jason C. G. Halford in:

Competing interests

J.C.G.H declares associations with AstraZeneca, American Beverage Association, Bristol-Myers Squibb, Novo Nordisk and Orexigen. C.A.R declares no competing interests.

Corresponding author

Correspondence to Carl A. Roberts.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing